RT Journal Article
T1 Golimumab in refractory uveitis related to spondyloarthritis. Multicenter study of 15 patients.
A1 Calvo-Río, Vanesa
A1 Blanco, Ricardo
A1 Santos-Gómez, Montserrat
A1 Rubio-Romero, Esteban
A1 Cordero-Coma, Miguel
A1 Gallego-Flores, Adela
A1 Veroz, Raúl
A1 Torre, Ignacio
A1 Hernández, Félix Francisco
A1 Atanes, Antonio
A1 Loricera, Javier
A1 González-Vela, M C
A1 Palmou, Natalia
A1 Hernández, José L
A1 González-Gay, Miguel A
K1 Anti-TNF-α therapy
K1 Golimumab
K1 Refractory
K1 Spondyloarthritis
K1 Uveitis
AB To assess the efficacy of golimumab (GLM) in refractory uveitis associated to spondyloarthritis (SpA). Multicenter study of SpA-related uveitis refractory to at least 1 immunosuppressive drug. The main outcome variables were degree of anterior and posterior chamber inflammation, visual acuity, and macular thickness. A total of 15 patients (13 men/2 women; 18 affected eyes; mean age 39 ± 6 years) were evaluated. The underlying SpA subtypes were ankylosing spondylitis (n = 8), psoriatic arthritis (n = 6) and non-radiographic axial SpA (n = 1). The ocular involvement patterns were recurrent anterior uveitis in 8 patients and chronic anterior uveitis in 7. Before GLM they have received methotrexate (n = 13), sulfasalazine (n = 6), pulses of methylprednisolone (n = 4), azathioprine (n = 3), leflunomide (n = 2), and cyclosporine (n = 1). Overall, 10 of them had also been treated with TNF-α blockers; etanercept (n = 7), adalimumab (n = 7), infliximab (n = 6), and certolizumab (n = 1). GLM was given at the standard dose (50mg/sc/monthly) as monotherapy (n = 7) or in combination with conventional immunosuppressive drugs (n = 8), mainly methotrexate. Most patients had rapid and progressive improvement of intraocular inflammation parameters. The median number of cells in the anterior chamber at 2 years [0 (0-0)] was significantly reduced compared to baseline findings [1 (0-3); p = 0.04]. The mean best corrected visual acuity value also improved (0.84 ± 0.3 at 2 years versus 0.62 ± 0.3 at baseline; p = 0.03). Only minor side effects were observed after a mean follow-up of 23 ± 7 months. Our results indicate that GLM may be a useful therapeutic option in refractory SpA-related uveitis.
YR 2016
FD 2016-03-09
LK http://hdl.handle.net/10668/9980
UL http://hdl.handle.net/10668/9980
LA en
DS RISalud
RD Apr 5, 2025